Market Place
Sourcing Support
Citius Pharma Launches $5M Direct Offering Under Nasdaq Rules
24 Apr 2026 //
PR NEWSWIRE
Citius Pharma Secures $3.8M From Nj Economic Development Program
24 Feb 2026 //
PR NEWSWIRE
Citius Pharma Reveals Fy2025 Financials And Business Update
24 Dec 2025 //
PR NEWSWIRE
Citius Oncology Reports Fy2025 Results & Business Update
24 Dec 2025 //
PR NEWSWIRE
Citius Oncology Closes $18M Offering Under Nasdaq Rules
10 Dec 2025 //
PR NEWSWIRE
Citius Oncology Announces $18M Direct Offering and Private
09 Dec 2025 //
PR NEWSWIRE
Citius Pharma Closes $6.0M Direct Offering Under Nasdaq Rules
22 Oct 2025 //
PR NEWSWIRE
Citius Pharma Launches $6.0M Direct Offering On Nasdaq Rule
21 Oct 2025 //
PR NEWSWIRE
Citius Pharma, Citius Oncology To Join October 2025 Conferences
17 Oct 2025 //
PR NEWSWIRE
Citius Signs Exclusive Commercialization Agreement with Eversana
16 Oct 2025 //
PR NEWSWIRE
Citius Oncology Closes $9.0M Direct Offering & Private Placement
11 Sep 2025 //
PR NEWSWIRE
Citius Pharmaceuticals Q3 2025 Financial Results & Update
12 Aug 2025 //
PR NEWSWIRE
Citius Oncology Announces Closing of $9.0 Million Public Offering
17 Jul 2025 //
PR NEWSWIRE
Citius Pharmaceuticals Meets Nasdaq Minimum Bid Price Requirement
09 Jul 2025 //
PR NEWSWIRE
Citius Pharmaceuticals Closes $15.8M Offering Under Nasdaq Rules
12 Jun 2025 //
PR NEWSWIRE
Citius Pharmaceuticals Announces $15.8M Direct Offering
10 Jun 2025 //
PR NEWSWIRE
Citius Pharmaceuticals Reports Q2 2025 Financial Results
14 May 2025 //
PR NEWSWIRE
Citius Pharmaceuticals to Present at Jefferies Conference
05 May 2025 //
PR NEWSWIRE
Citius Pharmaceuticals Announces $2M Stock Offering
01 Apr 2025 //
PR NEWSWIRE
Citius Pharma Reports Fiscal Q1 2025 Financial Results
14 Feb 2025 //
PR NEWSWIRE
Citius Pharma Announces Permanent J-Code for LYMPHIR by CMS
06 Feb 2025 //
PR NEWSWIRE
Citius Pharma Announces $3 Million Registered Direct Offering
08 Jan 2025 //
PR NEWSWIRE
Citius Plans LYMPHIR Commercial Launch In First Half Of 2025
07 Jan 2025 //
PR NEWSWIRE
Citius Pharmaceuticals Reports 2024 Financial Results and Update
27 Dec 2024 //
PR NEWSWIRE
Citius Pharma Reports FDA Meeting on Phase 3 Mino-Lok® Program
25 Nov 2024 //
PR NEWSWIRE
Citius Pharmaceuticals Announces 1-for-25 Reverse Stock Split
22 Nov 2024 //
PR NEWSWIRE
Citius Pharmaceuticals Announces $3 Million Direct Offering
15 Nov 2024 //
PR NEWSWIRE
Citius Pharmaceuticals` LYMPHIR™ Added to NCCN Guidelines in Oncology
05 Sep 2024 //
PR NEWSWIRE
Citius Pharmaceuticals to Join H.C. Wainwright Global Investment Conference
05 Sep 2024 //
PR NEWSWIRE
Citius Pharmaceuticals To Host Investor Call On Recent Developments
12 Aug 2024 //
PR NEWSWIRE
Citius Completes Merger To Form Citius Oncology, Inc.
12 Aug 2024 //
PR NEWSWIRE
Citius Pharmaceuticals Reports Q3 2024 Results And Business Update
12 Aug 2024 //
PR NEWSWIRE
Citius Pharma Announces Shareholder Approval Of Oncology Merger
05 Aug 2024 //
PR NEWSWIRE
Citius Pharmaceuticals Details Near-Term Milestones for Late-Stage Candidates
10 Jul 2024 //
PR NEWSWIRE
Citius To Host Call On Mino-Lok Phase 3 Topline Results
30 May 2024 //
PR NEWSWIRE
Citius Achieves Mino-Lok Phase 3 Primary, Secondary Endpoints
21 May 2024 //
PR NEWSWIRE
Citius Pharma Reports Fiscal Q2 2024 Results, Business Update
14 May 2024 //
PR NEWSWIRE
Citius At Upcoming EF Hutton, HC Wainwright Conferences
10 May 2024 //
PR NEWSWIRE
Citius Pharmaceuticals Announces $15 Million Registered Direct Offering
26 Apr 2024 //
PR NEWSWIRE
Citius Adds City Of Hope To UMN LYMPHIR + CAR-T Trial
11 Apr 2024 //
PR NEWSWIRE
Citius Pharma to Present at the LD Micro Invitational XIV Investor Conference
04 Apr 2024 //
PR NEWSWIRE
Citius Pharmaceuticals, Inc. Secures $2.4 million through New Jersey Program
07 Mar 2024 //
PR NEWSWIRE
Citius Pharmaceuticals Announces Filing of Form S-3 Shelf Registration Statement
26 Feb 2024 //
PR NEWSWIRE
Citius to Participate in Upcoming BIO CEO and Sidoti Investor Conferences
23 Feb 2024 //
PR NEWSWIRE
Citius Pharmaceuticals, Inc. Reports Fiscal First Quarter 2024 Financial Results
14 Feb 2024 //
PR NEWSWIRE
Citius Announces Nomination of Executive Robert J. Smith to Board of Directors
23 Jan 2024 //
PR NEWSWIRE
Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2023 Financial Results
02 Jan 2024 //
PR NEWSWIRE
Citius Completes Enrollment in Phase 3 Trial of Mino-Lok to Salvage Catheters
02 Jan 2024 //
PR NEWSWIRE
Citius Pharmaceuticals to Participate in the Sidoti Micro-Cap Virtual Conference
09 Nov 2023 //
PR NEWSWIRE
Citius Announces Publication of Positive Results from Tumor Study of LYMPHIR
31 Oct 2023 //
PR NEWSWIRE
Citius Pharmaceuticals Executes Definitive Agreement to Merge with TenX Keane
24 Oct 2023 //
PR NEWSWIRE
Citius Reschedules Participation in Sidoti Small-Cap Investor Conference
18 Sep 2023 //
PR NEWSWIRE
Citius Pharmaceuticals Mourns the Loss of Board Member, Howard Safir
13 Sep 2023 //
PR NEWSWIRE
Citius Pharmaceuticals looks to refile former Eisai cancer drug in early 2024
08 Sep 2023 //
ENDPTS
Citius to Participate in H.C. Wainwright and Sidoti Investor Conferences
06 Sep 2023 //
PR NEWSWIRE
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results
14 Aug 2023 //
PR NEWSWIRE
Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial
10 Aug 2023 //
PR NEWSWIRE
Citius` $40M gamble to revive Eisai`s Ontak hits wall at FDA
31 Jul 2023 //
FIERCE PHARMA
Citius Pharmaceuticals to be Added to Russell 3000® and Russell 2000® Indexes
26 Jun 2023 //
PR NEWSWIRE
Citius Pharmaceuticals files patent for Halo-Lido after Phase IIb trial
21 Jun 2023 //
CLINICAL TRIALS ARENA
